Abstract: The efficient scheduling of multi-task jobs across multiprocessor systems has become increasingly critical with the rapid expansion of computational systems. This challenge, known as ...

・Sarepta is set to exchange 1.25% convertible senior notes due 2027 for new 4.875% convertible senior notes due 2030, alongside about $31.6 million in cash. ・The transaction is slated to be completed ...

Fintel reports that on November 5, 2025, Mizuho upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Neutral to Outperform. Analyst Price Forecast Suggests 103.74% Upside As of October ...

An artificial-intelligence algorithm that discovers its own way to learn achieves state-of-the-art performance, including on some tasks it had never encountered before. Joel Lehman is at Lila Sciences ...

We recently published 10 Stocks With Double-Digit Upsides. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top performers on Thursday. Sarepta Therapeutics extended its winning streak to a 5th ...

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported second-quarter net income of $196.9 million. On a per-share basis, the Cambridge, ...

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the September 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer recently discussed. Sarepta ...

Despite an FDA request to halt shipments, Sarepta Therapeutics (NASDAQ:SRPT) announced late Friday that the company will continue to ship its gene therapy Elevidys, developed with Roche (OTCQX:RHHBY), ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) continued to fall on Friday as Reuters reported that the U.S. FDA plans to request the company to voluntarily halt all shipments of its gene therapy, ...